培美曲塞二线治疗老年晚期非小细胞肺癌的临床观察

Clinical observation of pemetrexed in the treatment of elderly patients with advanced stage non-small-cell lung carcinoma as a second-line regimen

目的:观察单药培美曲塞二线治疗老年晚期非小细胞肺癌(non-small-cell lung carcinoma,NSCLC)的临床疗效及不良反应。方法:经病理学或细胞学确诊,经一线治疗后复发的老年晚期NSCLC患者28例,其中男15例,女13例,予培美曲塞500 mg/m2静脉滴注,d1,21 d为l周期。至少治疗2个周期以上评价疗效和不良反应。结果:28例患者总有效率为25.00%,其中无完全缓解病例,部分缓解7例,稳定8例,无效13例,临床获益率为53.57%,中位进展期为3.2个月,主要不良反应为骨髓抑制及消化道反应。结论:培美曲塞二线治疗老年晚期NSCLC安全有效,不良反应轻,耐受性好。

Objective: To observe the efficacy and toxic reaction of pemetrexed in the treatment of elderly patients with advanced stage non-small-cell lung carcinoma as a second-line regiment.Methods: Confirmed by pathology or cytology,twenty-eight relapse patients were treated with pemetrexed through an intravenous drip on the first day( 500 mg /m2),each cycle was repeated every21 days. The treatment was finished at least 2 cycles. Results: The overall response rate was25. 00%,complete response was not achieved in all cases,7 cases had partial response,8 cases had stable disease and no response in 13 cases. The clinical benefit rate was 53. 57%,the median time to progression was 3. 2 months,the main toxic reactions were leucopenia and gastrointestinal response. Conclusion: As a second-line regimen for the treatment of elderly patients with advanced stage non-small-cell lung carcinoma,pemetrexed was effective and the toxic reaction could be tolerated.